137 related articles for article (PubMed ID: 36754959)
21. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function.
Kindle KB; Troke PJ; Collins HM; Matsuda S; Bossi D; Bellodi C; Kalkhoven E; Salomoni P; Pelicci PG; Minucci S; Heery DM
Mol Cell Biol; 2005 Feb; 25(3):988-1002. PubMed ID: 15657427
[TBL] [Abstract][Full Text] [Related]
22. [FGFR1 and MOZ, two key genes involved in malignant hemopathies linked to rearrangements within the chromosomal region 8p11-12].
Pébusque MJ; Chaffanet M; Popovici C; Birnbaum D
Bull Cancer; 2000 Dec; 87(12):887-94. PubMed ID: 11174118
[TBL] [Abstract][Full Text] [Related]
23. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase.
Champagne N; Pelletier N; Yang XJ
Oncogene; 2001 Jan; 20(3):404-9. PubMed ID: 11313971
[TBL] [Abstract][Full Text] [Related]
24. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34+ cells.
Paggetti J; Largeot A; Aucagne R; Jacquel A; Lagrange B; Yang XJ; Solary E; Bastie JN; Delva L
Oncogene; 2010 Sep; 29(36):5019-31. PubMed ID: 20581860
[TBL] [Abstract][Full Text] [Related]
25. A MOZ-TIF2 leukemia mouse model displays KAT6-dependent H3K23 propionylation and overexpression of a set of active developmental genes.
Smolko AE; Sullivan DW; Olsen SN; Kang H; Whedon SD; Baell JB; Cole PA; Armstrong SA; Kuroda MI
Proc Natl Acad Sci U S A; 2024 Jun; 121(26):e2405905121. PubMed ID: 38889153
[TBL] [Abstract][Full Text] [Related]
26. Recognition of unmodified histone H3 by the first PHD finger of bromodomain-PHD finger protein 2 provides insights into the regulation of histone acetyltransferases monocytic leukemic zinc-finger protein (MOZ) and MOZ-related factor (MORF).
Qin S; Jin L; Zhang J; Liu L; Ji P; Wu M; Wu J; Shi Y
J Biol Chem; 2011 Oct; 286(42):36944-55. PubMed ID: 21880731
[TBL] [Abstract][Full Text] [Related]
27. MOZ and MORF acetyltransferases: Molecular interaction, animal development and human disease.
Yang XJ
Biochim Biophys Acta; 2015 Aug; 1853(8):1818-26. PubMed ID: 25920810
[TBL] [Abstract][Full Text] [Related]
28. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11).
Imamura T; Kakazu N; Hibi S; Morimoto A; Fukushima Y; Ijuin I; Hada S; Kitabayashi I; Abe T; Imashuku S
Genes Chromosomes Cancer; 2003 Apr; 36(4):413-9. PubMed ID: 12619166
[TBL] [Abstract][Full Text] [Related]
29. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein.
Kitabayashi I; Aikawa Y; Nguyen LA; Yokoyama A; Ohki M
EMBO J; 2001 Dec; 20(24):7184-96. PubMed ID: 11742995
[TBL] [Abstract][Full Text] [Related]
30. Recognition of Histone H3K14 Acylation by MORF.
Klein BJ; Simithy J; Wang X; Ahn J; Andrews FH; Zhang Y; Côté J; Shi X; Garcia BA; Kutateladze TG
Structure; 2017 Apr; 25(4):650-654.e2. PubMed ID: 28286003
[TBL] [Abstract][Full Text] [Related]
31. Symplekin, a polyadenylation factor, prevents MOZ and MLL activity on HOXA9 in hematopoietic cells.
Largeot A; Paggetti J; Broséus J; Aucagne R; Lagrange B; Martin RZ; Berthelet J; Quéré R; Lucchi G; Ducoroy P; Bastie JN; Delva L
Biochim Biophys Acta; 2013 Dec; 1833(12):3054-3063. PubMed ID: 23994619
[TBL] [Abstract][Full Text] [Related]
32. MOZ fusion proteins in acute myeloid leukaemia.
Troke PJ; Kindle KB; Collins HM; Heery DM
Biochem Soc Symp; 2006; (73):23-39. PubMed ID: 16626284
[TBL] [Abstract][Full Text] [Related]
33. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia.
Carapeti M; Aguiar RC; Goldman JM; Cross NC
Blood; 1998 May; 91(9):3127-33. PubMed ID: 9558366
[TBL] [Abstract][Full Text] [Related]
34. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2.
Liang J; Prouty L; Williams BJ; Dayton MA; Blanchard KL
Blood; 1998 Sep; 92(6):2118-22. PubMed ID: 9731070
[TBL] [Abstract][Full Text] [Related]
35. RT-PCR analysis of the MOZ-CBP and CBP-MOZ chimeric transcripts in acute myeloid leukemias with t(8;16)(p11;p13).
Panagopoulos I; Isaksson M; Lindvall C; Björkholm M; Ahlgren T; Fioretos T; Heim S; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2000 Aug; 28(4):415-24. PubMed ID: 10862050
[TBL] [Abstract][Full Text] [Related]
36. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.
Deguchi K; Ayton PM; Carapeti M; Kutok JL; Snyder CS; Williams IR; Cross NC; Glass CK; Cleary ML; Gilliland DG
Cancer Cell; 2003 Mar; 3(3):259-71. PubMed ID: 12676584
[TBL] [Abstract][Full Text] [Related]
37. The MOZ-BRPF1 acetyltransferase complex in epigenetic crosstalk linked to gene regulation, development, and human diseases.
Viita T; Côté J
Front Cell Dev Biol; 2022; 10():1115903. PubMed ID: 36712963
[TBL] [Abstract][Full Text] [Related]
38. MOZ increases p53 acetylation and premature senescence through its complex formation with PML.
Rokudai S; Laptenko O; Arnal SM; Taya Y; Kitabayashi I; Prives C
Proc Natl Acad Sci U S A; 2013 Mar; 110(10):3895-900. PubMed ID: 23431171
[TBL] [Abstract][Full Text] [Related]
39. MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.
Sheikh BN; Phipson B; El-Saafin F; Vanyai HK; Downer NL; Bird MJ; Kueh AJ; May RE; Smyth GK; Voss AK; Thomas T
Oncogene; 2015 Nov; 34(47):5807-20. PubMed ID: 25772242
[TBL] [Abstract][Full Text] [Related]
40. Genomic characterization of MOZ/CBP and CBP/MOZ chimeras in acute myeloid leukemia suggests the involvement of a damage-repair mechanism in the origin of the t(8;16)(p11;p13).
Panagopoulos I; Isaksson M; Lindvall C; Hagemeijer A; Mitelman F; Johansson B
Genes Chromosomes Cancer; 2003 Jan; 36(1):90-8. PubMed ID: 12461753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
